Aernoud Fiolet

224 Chapter 8 Figure 1. Incidence rate of the primary end point by prior ACS status. The effect of colchicine 0.5mg once daily versus placebo on the incidence per 100 person-years of the composite end point of cardiovascular death, myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization. Subgroups divided by time since most recent prior acute coronary syndrome at randomization. Patients with very remote acute coronary syndrome remain at high risk for major adverse cardiovascular events highlighting the importance of compliance with long-term secondary prevention therapies, including the use of anti-inflammatory therapy. ACS = acute coronary syndrome. Figure 2. Efficacy of colchicine by prior ACS status. The effect of colchicine 0.5mg once daily versus placebo on the composite end point of cardiovascular death, myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization. Subgroups divided by prior acute coronary syndrome (ACS) status at randomization, both binary and with time-intervals, and interaction in these two groups was assessed. The hazard ratios with 95% confidence intervals were estimated from Cox proportional hazard models and visualized in a forest plot. The reduction of the composite end point by colchicine was consistent across the subgroups and no interaction was found, which suggests that the benefits of colchicine are consistent irrespective of history and timing of prior ACS. ACS = acute coronary syndrome; NNT = number needed to treat for one year.